Scott Filosi, Luzsana Biotechnology CEO

Chi­nese phar­ma gi­ant Hen­grui launch­es new com­pa­ny for glob­al­iza­tion play — with a Mer­ck KGaA vet at the helm

It is not un­com­mon for a large com­pa­ny to want to ex­pand its reach in­ter­na­tion­al­ly and this is typ­i­cal­ly done by part­ner­ing with com­pa­nies to test the wa­ter or es­tab­lish­ing a satel­lite of­fice and then get­ting to work on some projects. How­ev­er, a ma­jor Chi­nese phar­ma is go­ing all in.

Jiang­su Hen­grui has launched Luzsana Biotech­nol­o­gy to serve as an arm to de­vel­op and de­liv­er ther­a­peu­tics out­side of the Chi­nese mar­ket. Serv­ing as a whol­ly owned sub­sidiary of Hen­grui Phar­ma, Luzsana will be pro­vid­ed Hen­grui’s pipeline of pro­grams, span­ning over 250 clin­i­cal stud­ies, to de­vel­op and even­tu­al­ly com­mer­cial­ize.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.